Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ:EXAS) reported strong Q2 2025 results with record revenue of $811 million, up 16% year-over-year. The company's Screening segment generated $628 million (18% growth) while Precision Oncology contributed $183 million (9% growth).

Key developments include an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests, Medicare coverage for Oncodetect™, and a productivity plan targeting $150 million in annual savings by 2026. The company raised its full-year 2025 guidance, increasing revenue midpoint by $55 million to $3.13-3.17 billion and adjusted EBITDA midpoint by $25 million to $455-475 million.

Financial highlights include improved adjusted EBITDA of $138 million (26% increase), reduced net loss to $1 million, and strong cash position of $858 million.

Exact Sciences (NASDAQ: EXAS) has expanded its partnership with Humana to provide broader access to colorectal cancer screening through Cologuard Plus™. Starting August 2025, the non-invasive screening test will be available as an in-network service for eligible Humana Medicare Advantage members across the nation.

The partnership targets Humana's 5.8 million Medicare Advantage members, making Cologuard Plus™ more accessible for at-home colorectal cancer screening. The test, which launched in March 2025, has secured FDA approval, Medicare coverage, and inclusion in U.S. Preventive Services Task Force guidelines.

Exact Sciences (NASDAQ: EXAS), a leader in cancer screening and diagnostic tests, has scheduled its second quarter 2025 earnings release for August 6, 2025, after U.S. market close. Management will host a conference call and webcast at 5:00 PM ET on the same day to discuss the company's financial performance and business developments.

The webcast will be accessible through the company's website, with dial-in options available for both domestic (888-330-2384) and international (+1 240-789-2701) participants using access code 4437608. A replay will be made available on the company's website following the live event.

Exact Sciences (NASDAQ:EXAS) has secured Medicare coverage for its Oncodetect™ molecular residual disease (MRD) test through CMS's MolDX program. The coverage applies to patients with stage II, III, and resectable stage IV colorectal cancer for a five-year period.

The Oncodetect test can track up to 200 ctDNA variants and detect cancer recurrence up to two years earlier than imaging alone. The test's effectiveness is supported by clinical validation studies, including Beta-CORRECT and Alpha-CORRECT trials. This Medicare coverage decision impacts over three million Americans eligible for MRD testing across multiple solid tumors.

Exact Sciences (NASDAQ: EXAS) announced significant advancements for its Oncodetect™ molecular residual disease (MRD) test. The Beta-CORRECT study, to be presented at ASCO 2025, validates the test's effectiveness in predicting colorectal cancer recurrence for stages II-IV. Key findings show patients with ctDNA-positive results demonstrated 24- and 37-fold increased risk of recurrence after therapy and during surveillance, respectively. The company also revealed plans to launch a next-generation version of Oncodetect in 2026, powered by the Broad Institute's MAESTRO technology. This enhanced version will track up to 5,000 patient-specific variants and detect ctDNA levels below 1 part per million, offering improved sensitivity and broader clinical utility. The study included over 400 patients, making it Exact Sciences' largest MRD clinical study to date.

Exact Sciences (NASDAQ: EXAS), a leading cancer screening and diagnostic tests provider, has announced its participation in the upcoming William Blair 45th Annual Growth Stock Conference in Chicago. The company's management will deliver a presentation on Tuesday, June 3, 2025, at 9:40 a.m. ET. Investors can access the webcast through the investor relations section of Exact Sciences' website.

Exact Sciences (NASDAQ: EXAS) will present ten abstracts at ASCO 2025, showcasing advancements in cancer detection and precision oncology. Key highlights include:

The Oncodetect™ molecular residual disease (MRD) test shows promising results from the Beta-CORRECT study for stage II-IV colorectal cancer patients. A partnership with Flatiron Health continues enrollment for evaluating MRD testing across multiple solid tumors.

Their multi-cancer early detection (MCED) research reveals potential to reduce late-stage cancer incidence by >40% and mortality by up to 18% in high-risk groups. The company plans to launch Cancerguard™ EX, their MCED lab-developed test, in H2 2025.

The presentation will also feature new data on the Oncotype DX Breast Recurrence Score® test and Cologuard® test, reinforcing their role in cancer screening and treatment decisions. The Falcon registry study will track 25,000 participants against 50,000 standard-care patients to assess MCED test outcomes.

Exact Sciences (NASDAQ: EXAS) has achieved the 2025 Great Place To Work® Certification™ for the seventh consecutive year in the U.S., while also earning first-time certifications in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The certification is based on confidential employee surveys, with 77% of employees rating Exact Sciences positively - 20 points above the U.S. company average. The recognition evaluates workplace culture, employee experience, and leadership behaviors. According to research, certified workplaces show significant advantages: employees are 93% more likely to look forward to work, twice as likely to receive fair pay and promotions, and job seekers are 4.5 times more likely to find good leadership at certified companies.

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, has announced its upcoming participation in the BofA Securities Health Care Conference in Las Vegas. Company management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 p.m. ET (10:40 a.m. PT). Investors can access the webcast through the investor relations section of Exact Sciences' website at www.exactsciences.com.